The patents, held by VeriChip partner Receptors LLC, relate to biosensors that can detect the H1N1 and other viruses, and biological threats such as methicillin-resistant Staphylococcus aureus, VeriChip said in a statement.The technology will combine with VeriChip's implantable radio frequency identification devices to develop virus triage detection systems.'
Read more...